Tirzepatide
Brand names: Mounjaro, Zepbound
Part of: GLP-1 drugs
At a glance
- Medicare prescriptions, 2024
- 4,643,053
- Medicare drug cost
- $5.76B
- Average cost per prescription
- $1,241
- Clinicians who prescribed it
- 96,220
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 28.3%
- Internal Medicine 22.0%
- Nurse Practitioners 21.9%
- Endocrinology & Diabetes 15.9%
- Physician Assistants 7.1%
- Cardiology 0.9%
- General Practice 0.6%
- Nephrology (Kidney) 0.4%
- Geriatric Medicine 0.4%
- Pharmacists 0.4%
- Obesity Medicine 0.3%
- Interventional Cardiology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2022–2024
Medicare prescriptions rose 4,116% from 2022 to 2024.
Biggest change by state since 2022
- Florida +4,929%
- New York +4,462%
- California +3,795%
- Texas +3,627%
- Georgia +3,516%
- Alabama (smallest change) +2,731%
- Tennessee (smallest change) +2,942%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $19.3M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Lilly USA, LLC $19.1M
- Eli Lilly and Company $220,119
- Eli Lilly Export S.a. Puerto Rico Branch $15,710
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.